Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9214231 | 0.82 | AGTR1 (0.66) | HSP90AA1HSP90B1KCNH2AGTR1AGTR2 | |
| SCHEMBL6968500 | 0.79 | KCNH2 (0.53) | HSP90AA1HSP90B1KCNH2AGTR1AGTR2 | |
| SCHEMBL9269515 | 0.79 | KMT2A (0.51) | HSP90AA1HSP90B1ALDH1A1LMNA | |
| SCHEMBL11014930 | 0.78 | AGTR1 (0.61) | HSP90AA1HSP90B1KCNH2AGTR1AGTR2 | |
| SCHEMBL16486309 | 0.78 | AGTR1 (0.50) | HSP90AA1HSP90B1KCNH2AGTR1AGTR2 | |
| SCHEMBL9141531 | 0.78 | HSP90AA1 (0.48) | HSP90AA1HSP90B1AGTR1AGTR2 | |
| SCHEMBL11013827 | 0.77 | AGTR1 (0.60) | HSP90AA1HSP90B1KCNH2AGTR1AGTR2 | |
| SCHEMBL27714925 | 0.77 | KCNH2 (0.54) | HSP90AA1HSP90B1KCNH2AGTR1AGTR2 | |
| SCHEMBL5291955 | 0.77 | AGTR1 (0.60) | HSP90AA1HSP90B1KCNH2AGTR1AGTR2 | |
| SCHEMBL16136365 | 0.77 | HSP90AA1 (0.58) | HSP90AA1HSP90B1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187044-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-10-02 | — | — | US | disclosed |
| EP-0955294-B1 | Imidazolyl-alkenoic acid | SMITHKLINE BEECHAM CORP (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030166700-A1 | Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression | SMITHKLINE BEECHAM P.L.C. | 2003-09-04 | — | — | US | disclosed |
| US-20030096851-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-05-22 | — | — | US | disclosed |
| US-20030069293-A1 | Medicament | SMITHKLINE BEECHAM PLC | 2003-04-10 | — | — | US | disclosed |
| US-20030050285-A1 | Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke | SMITHKLINE BEECHAM P.L.C. | 2003-03-13 | — | — | US | disclosed |
| US-20030004201-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-01-02 | — | — | US | disclosed |
| US-20020160985-A1 | Medicament | SMITHKLINE BEECHAM PLC | 2002-10-31 | — | — | US | disclosed |
| US-20020132840-A1 | Treating angina in a mammal by administering an angiotensin II receptor antagonist. | SMITHKLINE BEECHAM P.1.C. | 2002-09-19 | — | — | US | disclosed |
| US-20020128300-A1 | Treating diabetic retinopathy in a mammal by administering an angiotensin II receptor antagonist. | SMITHKLINE BEECHAM P.L.C. | 2002-09-12 | — | — | US | disclosed |
| WO-1992010185-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE PREVENTION OF RESTINOSIS | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010186-A1 | USE OF ANGIOTENSN II RECEPTOR ANTAGONISTS FOR THE PREPARATION OF A MEDICAMENT FOR IMPROVING COGNITIVE FUNCTION | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992010184-A1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF ATHEROMA | SMITHKLINE BEECHAM PLC (GB) | 1992-06-25 | — | — | WO | disclosed |
| WO-1992002510-A1 | SUBSTITUTED [1H-IMIDAZOL-5-YL]ALKANOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-02-20 | — | — | WO | disclosed |
| WO-1992000068-A1 | SUBSTITUTED HISTIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 1992-01-09 | — | — | WO | disclosed |
| EP-0437103-A2 | Substituted 5-(alkyl)carboxamide imidazoles | SMITHKLINE BEECHAM CORPORATION (US) | 1991-07-17 | — | — | EP | disclosed |
| EP-0427463-A1 | Substituted N-(imidazolyl)alkyl alanine derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 1991-05-15 | — | — | EP | disclosed |
| EP-0425211-A1 | Substituted 5-((tetrazolyl)alkenyl)-imidazoles | SMITHKLINE BEECHAM CORPORATION (US) | 1991-05-02 | — | — | EP | disclosed |
| EP-0403158-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
| EP-0403159-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160985-A1 | Medicament | AGTR2, AGTR1, ACE | HSP90AA1 1431/4885HSP90B1 1475/4885KCNH2 1887/4885 |
| US-20020132840-A1 | Treating angina in a mammal by administering an angiotensin II receptor antagonist. | AGTR2, AGTR1, AGT | HSP90AA1 3391/4885HSP90B1 2514/4885KCNH2 256/4885 |
| US-20030187044-A1 | Medicament | AGTR2, AGTR1, ACE | HSP90AA1 2243/4885HSP90B1 2131/4885KCNH2 2965/4885 |
| US-20030004201-A1 | Medicament | AGTR2, AGTR1, ACE | HSP90AA1 2211/4885HSP90B1 943/4885KCNH2 3042/4885 |
| US-20030166700-A1 | Administering a substituted imidazoles to a mammal for the treatment of athroma progression and regression | AGTR1, AGTR2, AGT | HSP90AA1 3611/4885HSP90B1 2292/4885KCNH2 1639/4885 |
| US-20030096851-A1 | Medicament | AGTR2, AGTR1, ACE | HSP90AA1 2243/4885HSP90B1 2131/4885KCNH2 2965/4885 |
| US-20030050285-A1 | Substituted imidazoles; angiotensin II receptor antagonist for the treatment of hemorrhagic stroke | AGTR2, AGTR1, ACE | HSP90AA1 988/4885HSP90B1 1154/4885KCNH2 609/4885 |
| US-20030069293-A1 | Medicament | AGTR2, AGTR1, ACE | HSP90AA1 1431/4885HSP90B1 1475/4885KCNH2 1887/4885 |
| US-20020128300-A1 | Treating diabetic retinopathy in a mammal by administering an angiotensin II receptor antagonist. | AGTR2, AGTR1, REN | HSP90AA1 4451/4885HSP90B1 4117/4885KCNH2 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.